Managing Negative Symptoms of Schizophrenia: How Far Have We Come?

CNS Drugs

Volumn 31, Issue 5, 2017, Pages 373-388

  Kantrowitz, Joshua T ^a,b,c  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 288; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; BUNGAROTOXIN RECEPTOR; DEXTRO SERINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; GLYCINE; GLYCINE SITE MODULATOR; GLYCINE TRANSPORT INHIBITOR; GLYCINE TRANSPORTER; GSK 239512; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; MINOCYCLINE; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PIOGLITAZONE; PREGNENOLONE; UNCLASSIFIED DRUG;

BEHAVIOR THERAPY; BRAIN DEPTH STIMULATION; CLINICAL TRIAL (TOPIC); DANCE THERAPY; EXERCISE; HUMAN; MUSIC THERAPY; NEGATIVE SYMPTOM ASSESSMENT; NEGATIVE SYNDROME; NON INVASIVE PROCEDURE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIMARY NEGATIVE SYMPTOM; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SCHIZOPHRENIA ASSESSMENT; SECONDARY NEGATIVE SYMPTOM; ANIMAL; METABOLISM; PSYCHOLOGY;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 85027838348     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-017-0428-x     Document Type: Review

References (175)

1. Carpenter WT, Bartko JJ, Strauss JS, Hawk AB. Signs and symptoms as predictors of outcome: a report from the International Pilot Study of Schizophrenia. Am J Psychiatry. 1978;135(8):940–4.
2. Andreasen NC. Negative symptoms in schizophrenia. Arch Gen Psychiatry. 1982;39:784–8.
3. Goghari VM, Harrow M, Grossman LS, Rosen C. A 20-year multi-follow-up of hallucinations in schizophrenia, other psychotic, and mood disorders. Psychol Med. 2013;43(6):1151–60.
4. Heilbronner U, Samara M, Leucht S, Falkai P, Schulze TG. The longitudinal course of schizophrenia across the lifespan: clinical, cognitive, and neurobiological aspects. Harv Rev Psychiatry. 2016;24(2):118–28.
5. Mancevski B, Keilp J, Kurzon M, Berman RM, Ortakov V, Harkavy-Friedman J, et al. Lifelong course of positive and negative symptoms in chronically institutionalized patients with schizophrenia. Psychopathology. 2007;40(2):83–92.
6. Gur RE, Petty RG, Turetsky BI, Gur RC. Schizophrenia throughout life: sex differences in severity and profile of symptoms. Schizophr Res. 1996;21(1):1–12.
7. Pfohl B, Winokur G. The evolution of symptoms in institutionalized hebephrenic/catatonic schizophrenics. Br J Psychiatry. 1982;141:567–72.
8. Strauss JS, Carpenter WT Jr. The prediction of outcome in schizophrenia. I. Characteristics of outcome. Arch Gen Psychiatry. 1972;27(6):739–46.
9. Waters F, Aleman A, Fernyhough C, Allen P. Report on the inaugural meeting of the International Consortium on Hallucination Research: a clinical and research update and 16 consensus-set goals for future research. Schizophr Bull. 2012;38(2):258–62.
10. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007;33(4):1013–22.
11. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162(3):495–506.
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
13. Kurtz MM, Moberg JP, Ragland JD, Gur RC, Gur RE. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr Bull. 2005;31:167–74.
14. Fenton WS, McGlashan TH. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry. 1994;151(3):351–6.
15. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58(2):165–71.
16. Cohen AS, Saperstein AM, Gold JM, Kirkpatrick B, Carpenter WT Jr, Buchanan RW. Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull. 2007;33(5):1201–12.
17. Bobes J, Arango C, Garcia-Garcia M, Rejas J. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry. 2010;71(3):280–6.
18. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975;188(4194):1217–9.
19. 2 dopamine receptors in drug-naive schizophrenics. Science. 1986;234(4783):1558–63.
20. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.
21. Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385–92.
22. Lincoln TM, Dollfus S, Lyne J. Current developments and challenges in the assessment of negative symptoms. Schizophr Res. 2016. doi:10.1016/j.schres.2016.02.035.
23. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214–9.
24. Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RS. Methodological issues in negative symptom trials. Schizophr Bull. 2011;37(2):250–4.
25. Kay S, Fiszbein A, Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76.
26. Andreasen NC. The scale for the assessment of negative symptoms (SANS). Iowa City: University of Iowa; 1984.
27. Axelrod BN, Goldman RS, Alphs LD. Validation of the 16-item Negative Symptom Assessment. J Psychiatr Res. 1993;27(3):253–8.
28. Aleman A, Lincoln TM, Bruggeman R, Melle I, Arends J, Arango C, et al. Treatment of negative symptoms: where do we stand, and where do we go? Schizophr Res. 2017. doi:10.1016/j.schres.2016.05.015.
29. van Erp TG, Preda A, Nguyen D, Faziola L, Turner J, Bustillo J, et al. Converting positive and negative symptom scores between PANSS and SAPS/SANS. Schizophr Res. 2014;152(1):289–94.
30. Strauss GP, Gold JM. A psychometric comparison of the Clinical Assessment Interview for Negative Symptoms and the Brief Negative Symptom Scale. Schizophr Bull. 2016;42(6):1384–94.
31. Marder SR, Alphs L, Anghelescu IG, Arango C, Barnes TR, Caers I, et al. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res. 2013;150(2–3):328–33.
32. Insel TR. The NIMH experimental medicine initiative. World Psychiatry. 2015;14(2):151–3.
33. Lendrem DW, Lendrem BC. Torching the Haystack: modelling fast-fail strategies in drug development. Drug Discov Today. 2013;18(7–8):331–6.
34. Clark VP, Coffman BA, Mayer AR, Weisend MP, Lane TD, Calhoun VD, et al. TDCS guided using fMRI significantly accelerates learning to identify concealed objects. Neuroimage. 2012;59(1):117–28.
35. Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology. 2008;33(9):2187–99.
36. Kantrowitz JT, Epstein ML, Beggel O, Rohrig S, Lehrfeld JM, Revheim N, et al. Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist d-serine. Brain. 2016;139(Pt 12):3281–95.
37. Kantrowitz JT, Epstein ML, Lee M, Lehrfeld N, Nolan KA, Shope C, et al. Improvement in mismatch negativity generation during d-Serine treatment in schizophrenia: correlation with symptoms. Schizophr Res. 2017. doi:10.1016/j.schres.2017.02.027.
38. Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41(4):892–9.
39. Galderisi S, Farden A, Kaiser S. Dissecting negative symptoms of schizophrenia: history, assessment, pathophysiological mechanisms and treatment. Schizophr Res. 2016. doi:10.1016/j.schres.2016.04.046.
40. Garay RP, Citrome L, Samalin L, Liu CC, Thomsen MS, Correll CU, et al. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opin Pharmacother. 2016;17(7):921–36.
41. Arango C, Garibaldi G, Marder SR. Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr Res. 2013;150(2–3):346–52.
42. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301–8.
43. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199–214.
44. Moghaddam B, Krystal JH. Capturing the angel in “angel dust”: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull. 2012;38(5):942–9.
45. Coyle JT. NMDA receptor and schizophrenia: a brief history. Schizophr Bull. 2012;38(5):920–6.
46. Kantrowitz JT, Javitt DC. N-Methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull. 2010;83(3–4):108–21.
47. Kantrowitz JT, Javitt DC. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses. 2010;4(3):189–200.
48. Luby ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF. Model psychoses and schizophrenia. Am J Psychiatry. 1962;119:61–7.
49. Korostenskaja M, Kicic D, Kahkonen S. The effect of methylphenidate on auditory information processing in healthy volunteers: a combined EEG/MEG study. Psychopharmacology. 2008;197(3):475–86.
50. Umbricht D, Koller R, Vollenweider FX, Schmid L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol Psychiatry. 2002;51(5):400–6.
51. Umbricht D, Vollenweider FX, Schmid L, Grubel C, Skrabo A, Huber T, et al. Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology. 2003;28(1):170–81.
52. Mayer ML, Vyklicky L Jr, Clements J. Regulation of NMDA receptor desensitization in mouse hippocampal neurons by glycine. Nature. 1989;338(6214):425–7.
53. Vornov JJ, Coyle JT. Glutamate neurotoxicity and the inhibition of protein synthesis in the hippocampal slice. J Neurochem. 1991;56(3):996–1006.
54. Balu DT, Coyle JT. The NMDA receptor ‘glycine modulatory site’ in schizophrenia: d-serine, glycine, and beyond. Curr Opin Pharmacol. 2015;20:109–15.
55. Cho SE, Na KS, Cho SJ, Kang SG. Low d-serine levels in schizophrenia: a systematic review and meta-analysis. Neurosci Lett. 2016;634:42–51.
56. Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, et al. High dose d-serine in the treatment of schizophrenia. Schizophr Res. 2010;121(1–3):125–30.
57. Kantrowitz JT, Woods SW, Petkova E, Cornblatt B, Corcoran CM, Chen H, et al. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry. 2015;2(5):403–12.
58. Kantrowitz J, Javitt DC. Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry. 2012;25(2):96–102.
59. Javitt DC. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Dev. 2009;12(4):468–78.
60. Javitt DC, Sershen H, Hashim A, Lajtha A. Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology. 1997;17(3):202–4.
61. Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-d-aspartate receptor/glycine-site agonists. Neuropsychopharmacology. 2004;29(2):300–7.
62. Alberati D, Moreau JL, Lengyel J, Hauser N, Mory R, Borroni E, et al. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology. 2012;62(2):1152–61.
63. Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry. 2014;71(6):637–46.
64. Blaettler T, Bugarski-Kirola D, Fleischhacker WW, Bressan R, Arango C, Abi-Sabb D, et al. Efficacy and safety of adjunctive bitopertin (10 and 20 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics—results from the Phase III FlashLyte Study. Schizophr Res. 2014;158:e2–3.
65. Arango C, Nasrallah AT, Lawrie S, Lohmann TO, Zhu JL, Garibaldi G, et al. Efficacy and safety of adjunctive bitopertin (5 and 10 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics—results from the phase III DayLyte study. Schizophr Res. 2014;158(1–3):e1.
66. Bugarski-Kirola D, Iwata N, Sameljak S, Reid C, Blaettler T, Millar L, et al. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Lancet Psychiatry. 2016;3(12):1115–28.
67. Schoemaker JH, Jansen WT, Schipper J, Szegedi A. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. J Clin Psychopharmacol. 2014;34(2):190–8.
68. Dunayevich E, Buchanan RW, Chen CY, Yang J, Nilsen J, Dietrich JM, et al. Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia. Schizophr Res. 2017. doi:10.1016/j.schres.2016.10.027.
69. Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2004;55(5):452–6.
70. Javitt DC, Duncan L, Balla A, Sershen H. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry. 2005;10(3):275–87.
71. Lin CY, Liang SY, Chang YC, Ting SY, Kao CL, Wu YH, et al. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: a randomised, double-blind, placebo-controlled trial. World J Biol Psychiatry. doi:10.3109/15622975.2015.1117654.
72. Amiaz R, Kent I, Rubinstein K, Sela BA, Javitt D, Weiser M. Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia—preliminary study. Isr J Psychiatry Relat Sci. 2015;52(1):12–5.
73. Mantysalo S, Naatanen R. The duration of a neuronal trace of an auditory stimulus as indicated by event-related potentials. Biol Psychol. 1987;24(3):183–95.
74. Javitt DC. Intracortical mechanisms of mismatch negativity dysfunction in schizophrenia. Audiol Neurootol. 2000;5(3–4):207–15.
75. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. A new five factor model of schizophrenia. Psychiatr Q. 1994;65(4):299–322.
76. Kantrowitz JT, Nolan KA, Epstein M, Lehrfeld N, Shope C, Petkova E, et al. Neurophysiological effects of bitopertin in schizophrenia. J Clin Psychopharmacol. 2017;37(4) (in press).
77. Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, et al. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res. 2014;152(2–3):325–32.
78. Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry. 2005;162(2):394–6.
79. Kantrowitz JT, Milak MS, Mao X, Shungu DC, Mann JJ. d-Cycloserine, an NMDA glutamate receptor glycine site partial agonist, induces acute increases in brain glutamate plus glutamine and GABA comparable to ketamine. Am J Psychiatry. 2016;173(12):1241–2.
80. Milak MS, Proper CJ, Mulhern ST, Parter AL, Kegeles LS, Ogden RT, et al. A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol Psychiatry. 2015;21(3):320–7.
81. Strzelecki D, Podgorski M, Kaluzynska O, Stefanczyk L, Kotlicka-Antczak M, Gmitrowicz A, et al. Adding sarcosine to antipsychotic treatment in patients with stable schizophrenia changes the concentrations of neuronal and glial metabolites in the left dorsolateral prefrontal cortex. Int J Mol Sci. 2015;16(10):24475–89.
82. Strzelecki D, Podgorski M, Kaluzynska O, Gawlik-Kotelnicka O, Stefanczyk L, Kotlicka-Antczak M, et al. Supplementation of antipsychotic treatment with sarcosine—GlyT1 inhibitor—causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia. Neurosci Lett. 2015;606:7–12.
83. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17(8):2921–7.
84. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998;281(5381):1349–52.
85. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13(9):1102–7.
86. Stauffer VL, Millen BA, Andersen S, Kinon BJ, Lagrandeur L, Lindenmayer JP, et al. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res. 2013;150(2–3):434–41.
87. Kinon BJ, Adams DH, Baygani S, Millen B, Velona I, Kollack-Walker S. A long-term, phase 2, safety study of LY2140023 monohydrate vs. Atypical antipsychotic standard of care in schizophrenia. Schizophr Bull. 2011;37(Suppl 1):311.
88. Kinon BJ, Gomez JC. Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia. Neuropharmacology. 2013;66:82–6.
89. Litman RE, Smith MA, Doherty JJ, Cross A, Raines S, Gertsik L, et al. AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study. Schizophr Res. 2016;172(1–3):152–7.
90. Behrens MM, Sejnowski TJ. Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex? Neuropharmacology. 2009;57(3):193–200.
91. Iranpour N, Zandifar A, Farokhnia M, Goguol A, Yekehtaz H, Khodaie-Ardakani MR, et al. The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. Hum Psychopharmacol. 2016;31(2):103–12.
92. Wang JQ, Arora A, Yang L, Parelkar NK, Zhang G, Liu X, et al. Phosphorylation of AMPA receptors: mechanisms and synaptic plasticity. Mol Neurobiol. 2005;32(3):237–49.
93. Chaves C, Marque CR, Trzesniak C, Machado de Sousa JP, Zuardi AW, Crippa JA, et al. Glutamate-N-methyl-d-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update. Braz J Med Biol Res. 2009;42(11):1002–14.
94. Solmi M, Veronese N, Thapa N, Facchini S, Stubbs B, Fornaro M, et al. Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectr. 2017;9:1–12.
95. Marx CE, Lee J, Subramaniam M, Rapisarda A, Bautista DC, Chan E, et al. Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology. 2014;231(17):3647–62.
96. Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I, et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron. 2013;78(1):81–93.
97. Schobel SA, Lewandowski NM, Corcoran CM, Moore H, Brown T, Malaspina D, et al. Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry. 2009;66(9):938–46.
98. Gozzi A, Herdon H, Schwarz A, Bertani S, Crestan V, Turrini G, et al. Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat. Psychopharmacology. 2008;201(2):273–84.
99. Meyer EC, Carrion RE, Cornblatt BA, Addington J, Cadenhead KS, Cannon TD, et al. The relationship of neurocognition and negative symptoms to social and role functioning over time in individuals at clinical high risk in the first phase of the North American Prodrome Longitudinal Study. Schizophr Bull. 2014;40(6):1452–61.
100. Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D’Souza DC, et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuropsychopharmacol. 2013;23(8):931–40.
101. McGlashan TH, Miller TJ, Woods SW, Hoffman RE, Davidson L. Instrument for the assessment of prodromal symptoms and states. In: Miller M, McGlashan TH, editors. Early intervention in psychotic disorders. Dordrecht: Kluwer Academic Publishers; 2001. p. 135–49.
102. Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B, et al. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res. 2014;153(1–3):169–76.
103. Kinon BJ, Millen BA, Zhang L, McKinzie DL. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry. 2015;78(11):754–62.
104. Freedman R. alpha7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. Annu Rev Med. 2014;65:245–61.
105. Preskorn SH, Gawryl M, Dgetluck N, Palfreyman M, Bauer LO, Hilt DC. Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014;20(1):12–24.
106. Huang M, Felix AR, Flood DG, Bhuvaneswaran C, Hilt D, Koenig G, et al. The novel alpha7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology. 2014;231(23):4541–51.
107. Maex R, Grinevich VP, Grinevich V, Budygin E, Bencherif M, Gutkin B. Understanding the role alpha7 nicotinic receptors play in dopamine efflux in nucleus accumbens. ACS Chem Neurosci. 2014;5(10):1032–40.
108. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry. 1986;143(8):993–7.
109. Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry. 1997;42(1):1–5.
110. Freedman R, Adler LE, Bickford P, Byerley W, Coon H, Cullum CM, et al. Schizophrenia and nicotinic receptors. Harv Rev Psychiatry. 1994;2(4):179–92.
111. Javitt DC, Freedman R. Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia. Am J Psychiatry. 2015;172(1):17–31.
112. Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, et al. Randomized, double-blind, placebo-controlled study of encenicline, an alpha7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology. 2015;40(13):3053–60.
113. Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, et al. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology. 2013;38(6):968–75.
114. Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, et al. Phase 2 trial of an alpha-7 nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia. Schizophr Bull. 2016;42(2):335–43.
115. Umbricht D, Keefe RS, Murray S, Lowe DA, Porter R, Garibaldi G, et al. A randomized, placebo-controlled study investigating the nicotinic alpha7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2014;39(7):1568–77.
116. Haig GM, Bain EE, Robieson WZ, Baker JD, Othman AA. A randomized trial to assess the efficacy and safety of ABT-126, a selective alpha7 nicotinic acetylcholine receptor agonist, in the treatment of cognitive impairment in schizophrenia. Am J Psychiatry. 2016;173(8):827–35.
117. Gee KW, Olincy A, Kanner R, Johnson L, Hogenkamp D, Harris J, et al. First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288. J Psychopharmacol. 2017;31(4):434–41.
118. Helfer B, Samara MT, Huhn M, Klupp E, Leucht C, Zhu Y, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry. 2016;173(9):876–86.
119. Kantrowitz JT, Tampi RR. Risk of psychosis exacerbation by tricyclic antidepressants in unipolar major depressive disorder with psychotic features. J Affect Disord. 2008;106(3):279–84.
120. Nikbakhat MR, Arabzadeh S, Zeinoddini A, Khalili Z, Rezaei F, Mohammadinejad P, et al. Duloxetine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled Study. Pharmacopsychiatry. 2016;49(4):162–9.
121. Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132(2):500–6.
122. Buchanan RW, Weiner E, Kelly DL, Gold JM, Keller WR, Waltz JA, et al. Rasagiline in the treatment of the persistent negative symptoms of schizophrenia. Schizophr Bull. 2015;41(4):900–8.
123. Zheng W, Xiang YT, Xiang YQ, Li XB, Ungvari GS, Chiu HF, et al. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Acta Psychiatr Scand. 2016;134(5):385–98.
124. Glick ID, Bosch J, Casey DE. A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. J Clin Psychopharmacol. 2009;29(3):267–71.
125. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152–63.
126. Veerman SR, Schulte PF, Begemann MJ, de Haan L. Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. Pharmacopsychiatry. 2014;47(7):231–8.
127. Evins AE, Amico ET, Shih V, Goff DC. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J Neural Transm. 1997;104(6–7):761–6.
128. Neill JC, Grayson B, Kiss B, Gyertyan I, Ferguson P, Adham N. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur Neuropsychopharmacol. 2016;26(1):3–14.
129. Papp M, Gruca P, Lason-Tyburkiewicz M, Adham N, Kiss B, Gyertyan I. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol. 2014;25(5–6):567–74.
130. Nemeth G, Laszlovszky I, Czobor P, Szalai E, Szatmari B, Harsanyi J, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103–13.
131. Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science. 1991;251(4996):947–9.
132. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology. 1994;116(2):143–51.
133. Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, et al. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. J Psychopharmacol. 2016;30(5):428–35.
134. Andrade C, Kisely S, Monteiro I, Rao S. Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res. 2015;60:14–21.
135. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Progr Neurobiol. 2001;63(6):637–72.
136. Haig GM, Bain E, Robieson W, Othman AA, Baker J, Lenz RA. A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia. Schizophr Bull. 2014;40(6):1433–42.
137. Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, et al. A Phase II study of a histamine H(3) receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophr Res. 2015;164(1–3):136–42.
138. Shilling PD, Feifel D. Potential of oxytocin in the treatment of schizophrenia. CNS Drugs. 2016;30(3):193–208.
139. Oya K, Matsuda Y, Matsunaga S, Kishi T, Iwata N. Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci. 2016;266(5):439–50.
140. Clark VP, Coffman BA, Trumbo MC, Gasparovic C. Transcranial direct current stimulation (tDCS) produces localized and specific alterations in neurochemistry: a (1)H magnetic resonance spectroscopy study. Neurosci Lett. 2011;500(1):67–71.
141. Shi C, Yu X, Cheung EF, Shum DH, Chan RC. Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis. Psychiatry Res. 2014;215(3):505–13.
142. Dlabac-de Lange JJ, Bais L, van Es FD, Visser BG, Reinink E, Bakker B, et al. Efficacy of bilateral repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: results of a multicenter double-blind randomized controlled trial. Psychol Med. 2015;45(6):1263–75.
143. Li Z, Yin M, Lyu XL, Zhang LL, Du XD, Hung GC. Delayed effect of repetitive transcranial magnetic stimulation (rTMS) on negative symptoms of schizophrenia: findings from a randomized controlled trial. Psychiatry Res. 2016;240:333–5.
144. Wobrock T, Guse B, Cordes J, Wolwer W, Winterer G, Gaebel W, et al. Left prefrontal high-frequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicenter trial. Biol Psychiatry. 2015;77(11):979–88.
145. Priori A, Hallett M, Rothwell JC. Repetitive transcranial magnetic stimulation or transcranial direct current stimulation? Brain Stimul. 2009;2(4):241–5.
146. Kurimori M, Shiozawa P, Bikson M, Aboseria M, Cordeiro Q. Targeting negative symptoms in schizophrenia: results from a proof-of-concept trial assessing prefrontal anodic tDCS protocol. Schizophr Res. 2015;166(1–3):362–3.
147. Palm U, Keeser D, Hasan A, Kupka MJ, Blautzik J, Sarubin N, et al. Prefrontal transcranial direct current stimulation for treatment of schizophrenia with predominant negative symptoms: a double-blind, sham-controlled proof-of-concept study. Schizophr Bull. 2016;42(5):1253–61.
148. Gomes JS, Shiozawa P, Dias AM, Valverde Ducos D, Akiba H, Trevizol AP, et al. Left dorsolateral prefrontal cortex anodal tDCS effects on negative symptoms in schizophrenia. Brain Stimul. 2015;8(5):989–91.
149. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168(5):472–85.
150. Vinogradov S, Fisher M, de Villers-Sidani E. Cognitive training for impaired neural systems in neuropsychiatric illness. Neuropsychopharmacology. 2012;37(1):43–76.
151. Fisher M, Holland C, Merzenich MM, Vinogradov S. Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am J Psychiatry. 2009;166(7):805–11.
152. Kantrowitz JT, Sharif Z, Medalia A, Keefe RSE, Harvey PD, Bruder GE, et al. A multicenter, rater-blind, randomized controlled study of auditory processing focused cognitive remediation combined with open label lurasidone in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2016;77(6):799–806.
153. Velthorst E, Koeter M, van der Gaag M, Nieman DH, Fett AK, Smit F, et al. Adapted cognitive-behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression. Psychol Med. 2015;45(3):453–65.
154. Velligan DI, Roberts D, Mintz J, Maples N, Li X, Medellin E, et al. A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia. Schizophr Res. 2015;165(2–3):175–80.
155. Rakitzi S, Georgila P, Efthimiou K, Mueller DR. Efficacy and feasibility of the integrated psychological therapy for outpatients with schizophrenia in Greece: final results of a RCT. Psychiatry Res. 2016;242:137–43.
156. Calvo A, Moreno M, Ruiz-Sancho A, Rapado-Castro M, Moreno C, Sanchez-Gutierrez T, et al. Intervention for adolescents with early-onset psychosis and their families: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2014;53(6):688–96.
157. Gold R, Butler PD, Revheim N, Leitman DI, Hansen JA, Gur RC, et al. Auditory emotion recognition impairments in schizophrenia: relationship to acoustic features and cognition. Am J Psychiatry. 2012;169(4):424–32.
158. Leitman DI, Laukka P, Juslin PN, Saccente E, Butler P, Javitt DC. Getting the cue: sensory contributions to auditory emotion recognition impairments in schizophrenia. Schizophr Bull. 2010;36(3):545–56.
159. Penn DL, Sanna LJ, Roberts DL. Social cognition in schizophrenia: an overview. Schizophr Bull. 2008;34(3):408–11.
160. Kantrowitz JT, Hoptman MJ, Leitman DI, Moreno-Ortega M, Lehrfeld JM, Dias E, et al. Neural substrates of auditory emotion recognition deficits in schizophrenia. J Neurosci. 2015;35(44):14909–21.
161. Kantrowitz JT, Leitman DI, Lehrfeld JM, Laukka P, Juslin PN, Butler PD, et al. Reduction in tonal discriminations predicts receptive emotion processing deficits in schizophrenia and schizoaffective disorder. Schizophr Bull. 2013;39(1):86–93.
162. Green MF, Hellemann G, Horan WP, Lee J, Wynn JK. From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Arch Gen Psychiatry. 2012;69(12):1216–24.
163. Kantrowitz JT, Hoptman MJ, Leitman DI, Silipo G, Javitt DC. The 5% difference: early sensory processing predicts sarcasm perception in schizophrenia and schizo-affective disorder. Psychol Med. 2014;44(1):25–36.
164. Kalin M, Kaplan S, Gould F, Pinkham AE, Penn DL, Harvey PD. Social cognition, social competence, negative symptoms and social outcomes: inter-relationships in people with schizophrenia. J Psychiatr Res. 2015;68:254–60.
165. Escoffier N, Zhong J, Schirmer A, Qiu A. Emotional expressions in voice and music: same code, same effect? Hum Brain Map. 2013;34(8):1796–810.
166. Juslin P, Laukka P. Communication of emotions in vocal expression and music performance: different channels, same code? Psychol Bull. 2003;129(5):770–814.
167. Kantrowitz JT, Scaramello N, Jakubovitz A, Lehrfeld JM, Laukka P, Elfenbein HA, et al. Amusia and protolanguage impairments in schizophrenia. Psychol Med. 2014;44(13):2739–48.
168. Hatada S, Sawada K, Akamatsu M, Doi E, Minese M, Yamashita M, et al. Impaired musical ability in people with schizophrenia. J Psychiatry Neurosci. 2013;38(5):120207.
169. Tseng PT, Chen YW, Lin PY, Tu KY, Wang HY, Cheng YS, et al. Significant treatment effect of adjunct music therapy to standard treatment on the positive, negative, and mood symptoms of schizophrenic patients: a meta-analysis. BMC Psychiatry. 2016;26(16):16.
170. Firth J, Cotter J, Elliott R, French P, Yung AR. A systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol Med. 2015;45(7):1343–61.
171. Dauwan M, Begemann MJ, Heringa SM, Sommer IE. Exercise improves clinical symptoms, quality of life, global functioning, and depression in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2016;42(3):588–99.
172. Martin LA, Koch SC, Hirjak D, Fuchs T. Overcoming disembodiment: the effect of movement therapy on negative symptoms in schizophrenia—a multicenter randomized controlled trial. Front Psychol. 2016;7:483.
173. Röhricht F, Papadopoulos N. A treatment manual: body oriented psychological therapy for chronic schizophrenia. London: Newham Centre for Mental Health; 2010.
174. Agid O, Siu CO, Potkin SG, Kapur S, Watsky E, Vanderburg D, et al. Meta-regression analysis of placebo response in antipsychotic trials, 1970–2010. Am J Psychiatry. 2013;170(11):1335–44.
175. Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA. Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry. 2014;71(12):1409–21.